Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma-Reference-Cited by-同舟云学术

Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma

Published:2016 Issue:1 Volume:22 Page:275
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:en
Short-container-title:WJG

Author:

Haruyama Yukihiro

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference83 articles.

1. Global cancer statistics

2. Sorafenib in Advanced Hepatocellular Carcinoma

3. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma

4. Glypicans

5. Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, Puricelli L, de Kier Joffé EB. Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol 2008;23:1333-1340.

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. [⁶⁸Ga]Ga-RAYZ-8009: A Glypican-3–Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging—A First-in-Human Case Series;Journal of Nuclear Medicine;2024-09-12

2. Lipid metabolism-related long noncoding RNAs: A potential prognostic biomarker for hepatocellular carcinoma;World Journal of Gastroenterology;2024-09-07

3. 109Pd/109mAg in-vivo generator in the form of nanoparticles for combined β- - Auger electron therapy of hepatocellular carcinoma;EJNMMI Radiopharmacy and Chemistry;2024-08-13

4. Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma;Journal of Leukocyte Biology;2024-06-26

5. Radiomic Analysis of Contrast-Enhanced CT Predicts Glypican 3-Positive Hepatocellular Carcinoma;Current Medical Imaging Reviews;2024-04-25